维吾尔族特色植物药西瓜中特征性成分cucurbitacins靶向HIPK2治疗帕金森病的机制研究
批准号:
81803755
项目类别:
青年科学基金项目
资助金额:
21.0 万元
负责人:
王贯
依托单位:
学科分类:
H3208.中药神经精神药理
结题年份:
2021
批准年份:
2018
项目状态:
已结题
项目参与者:
何俊、印义琼、张瑾、舒洋、王晓云、杨磊、常潇洒、罗小娇
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
目前帕金森病(PD)的治疗没有靶向特效药物,为数不多的已上市药物因为疗效不佳或毒副作用较大难以满足患者需求。申请人在前期工作中发现,维吾尔族药用植物药西瓜的70%乙醇提取物具有显著抗PD作用,随后采用活性示踪分离方法获得了22个葫芦素型三萜类(cucurbitacins)成分,其中化合物KKY-02具有较优的抗PD活性。进一步研究证实KKY-02是通过靶向PD关键靶标HIPK2诱导神经细胞发生保护性自噬;动物实验表明,KKY-02能够显著改善PD模型小鼠的运动功能障碍,具体机制亟待深入研究。本课题拟在前期基础上,深入研究KKY-02对HIPK2的靶向性及其调控的自噬网络,探究该化合物通过靶向HIPK2诱导保护性自噬在体内外PD模型中的分子机制。本课题有望阐明KKY-02为代表的活性成分是否为药西瓜抗PD的物质基础,为药西瓜的开发利用以及新型抗PD民族药物的研发提供科学依据。
英文摘要
Currently, there are no effective targeted drugs for treatment of Parkinson’s disease (PD). Few drugs already on the market are difficult to meet the requirement due to the poor efficacy and side effects. The applicant in the stage of doctoral student's work found that the 70% ethanol extract of Citrullus Colocynthis (L.) Shrad, a characteristic plants in uygur medicine, has a significant anti-PD effect. Subsequently, 22 cucurbitacins components were obtained by the method of active tracing separation, which may be the drug efficacy material base of Citrullus Colocynthis. Further studies found that the compound KKY-02 has a good protective effect on PD. On the basis of this, we found that KKY-02 bind well to the active site of HIPK2, a key target for PD treatment through bioinformatics and system biology methods. Molecular biology experiments showed that KKY-02 might be used to induce cellular protective autophagy to exert a neuroprotective activity by targeting HIPK2. Animal experiments showed that KKY-02 could significantly improve motor dysfunction in MPTP-induced PD model mice, and its specific molecular mechanism needs further study. This topic is intended to further study the compound’s targeting of HIPK2 protein targeting and its regulation of autophagy network, to explore the role of the compound in targeting HIPK2 regulation of autophagy in vitro and in vivo. Taken together, the molecular mechanisms of these compounds will provide new methods and ideas for the precise development of PD therapeutic medicines. Further molecular pharmacology research on these molecules will also provide the foundations for functional study of autophagy in PD.
目前帕金森病(PD)的治疗没有靶向特效药物,为数不多的已上市药物因为疗效不佳或毒副作用较大难以满足患者需求。申请人在前期工作中发现,维吾尔族药用植物药西瓜的70%乙醇提取物具有显著抗PD作用,随后采用活性示踪分离方法获得了化合物KKY-02,该化合物具有较好的抗PD活性。在前期工作的基础上,我们使用LC-MS/MS鉴定了药西瓜的成分,使用网络药理学、生物信息学、分子对接、分子生物学、药理学等方法对KKY-02靶向HIPK2抗PD的作用和机制进行了探索研究,结果表明该化合物能够通过靶向HIPK2调控自噬从而发挥较好的抗PD作用,动物实验结果也表明该化合物在体内具有较好的抗PD效果,并且没有明显毒性作用。在本项目的资助下,项目负责人在Journal of the Taiwan Institute of Chemical Engineers, Acta Pharmaceutica Sinica B, Journal of Medicinal Chemistry等期刊发表了多篇学术论文。这些都为药西瓜这一民族药物抗PD的研发提供了一定的科学参考和基础。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.
使用小分子化合物靶向自噬以改善帕金森病的潜在疗法
DOI:10.1016/j.apsb.2021.02.016
发表时间:2021-10
期刊:Acta pharmaceutica Sinica. B
影响因子:--
作者:Zhang K;Zhu S;Li J;Jiang T;Feng L;Pei J;Wang G;Ouyang L;Liu B
通讯作者:Liu B
DOI:doi:10.1016/j.apsb.2021.02.016
发表时间:2021
期刊:Acta Pharmaceutica Sinica B
影响因子:14.5
作者:Kai Zhang;Shiou Zhu;Jiamei Li;Tingting Jiang;Lu Feng;Junping Pei;Guan Wang;Liang Ouyang;Bo Liu
通讯作者:Bo Liu
Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy
开发有效的 LC3 靶向 AUTAC 工具,通过选择性自噬进行蛋白质降解
DOI:10.1039/d1cc04661f
发表时间:2021
期刊:Chemical Communications
影响因子:4.9
作者:Pei Junping;Pan Xiaoli;Wang Aoxue;Shuai Wen;Bu Faqian;Tang Pan;Zhang Shuai;Zhang Yiwen;Wang Guan;Ouyang Liang
通讯作者:Ouyang Liang
The protective effects of citrullus colocynthis on inhibiting oxidative damage and autophagy-associated cell death in Parkinson's disease
西瓜对抑制帕金森病氧化损伤和自噬相关细胞死亡的保护作用
DOI:10.1016/j.jtice.2019.04.003
发表时间:2019-07-01
期刊:JOURNAL OF THE TAIWAN INSTITUTE OF CHEMICAL ENGINEERS
影响因子:5.7
作者:Chen, Yanmei;Sa, Yuliang;Liu, Bo
通讯作者:Liu, Bo
Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery
靶向溶酶体降解途径:药物发现的新策略和技术
DOI:10.1021/acs.jmedchem.0c01689
发表时间:2021
期刊:Journal of Medicinal Chemistry
影响因子:7.3
作者:Pei Junping;Wang Guan;Feng Lu;Zhang Jifa;Jiang Tingting;Sun Qiu;Ouyang Liang
通讯作者:Ouyang Liang
基于ERK1/2-ERK5代偿机制的共价抑制剂设计合成与抗肿瘤分子机制研究
- 批准号:22177083
- 项目类别:面上项目
- 资助金额:63万元
- 批准年份:2021
- 负责人:王贯
- 依托单位:
国内基金
海外基金















{{item.name}}会员


